Adaptin Bio
PublicAdaptin Bio is now publicly traded
The data on this page reflects Adaptin Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Convertible Debt
Mar 23, 2026
Total Funding Raised
$1.65M
Company Overview
Adaptin Bio Operating Corporation is a biotechnology company that develops novel therapies for oncology and central nervous system disorders with improved drug delivery to the brain and other tissues.
AI Layer
Non-AI
Keywords
Adaptin Bio Comparables
Compare Adaptin Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Altido Therapeutics | 85% | |
| Mesenkia Therapeutics AB | 81% |
Adaptin Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Mar 23, 2026 |
Key People
Founding team and executive leadership
Adaptin Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access